{"id":"capox-6-month","safety":{"commonSideEffects":[{"rate":"45%","effect":"Hand-foot syndrome"},{"rate":"30%","effect":"Diarrhea"},{"rate":"25%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Capecitabine is a prodrug of 5-fluorouracil (5-FU), which is a thymidylate synthase inhibitor. This mechanism leads to the inhibition of DNA synthesis and cell death in rapidly dividing cancer cells.","oneSentence":"Capecitabine is a thymidylate synthase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:04.390Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Breast cancer"},{"name":"Stomach cancer"}]},"trialDetails":[{"nctId":"NCT07001748","phase":"PHASE2, PHASE3","title":"Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2025-08-19","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis","enrollment":148},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT05174169","phase":"PHASE2, PHASE3","title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-10","conditions":"Stage III Colon Cancer","enrollment":1912},{"nctId":"NCT06107920","phase":"PHASE3","title":"Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-05-07","conditions":"Colon Cancer","enrollment":232},{"nctId":"NCT07340567","phase":"PHASE3","title":"Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-01","conditions":"Colorectal Cancer","enrollment":2450},{"nctId":"NCT07328087","phase":"EARLY_PHASE1","title":"COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV","enrollment":12},{"nctId":"NCT05008809","phase":"PHASE3","title":"Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)","status":"RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2021-12-06","conditions":"Colorectal Cancer","enrollment":507},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT07188025","phase":"PHASE3","title":"ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-10","conditions":"Rectal Cancer","enrollment":103},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT07059949","phase":"PHASE2","title":"Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-30","conditions":"Unresectable Metastatic Rectal Cancer, CAPOX, Combination of Radioimmunotherapy","enrollment":80},{"nctId":"NCT06899477","phase":"PHASE3","title":"Pre-Operative Treatment in REseCTable COlon CanceR","status":"NOT_YET_RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2025-04","conditions":"Colo-rectal Cancer, Colon Cancer, Colon Carcinoma","enrollment":714},{"nctId":"NCT06753721","phase":"PHASE1, PHASE2","title":"An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-12-31","conditions":"Advanced Colorectal Adenocarcinoma","enrollment":13},{"nctId":"NCT04488159","phase":"PHASE3","title":"Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer","status":"WITHDRAWN","sponsor":"Johannes Laengle, MD, PhD","startDate":"2024-12-01","conditions":"Colon Cancer Stage III","enrollment":""},{"nctId":"NCT06194981","phase":"","title":"Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-01-11","conditions":"Gastric Cancer","enrollment":260},{"nctId":"NCT05862051","phase":"NA","title":"RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-14","conditions":"Colorectal Cancer, Oligometastatic Disease","enrollment":75},{"nctId":"NCT00958737","phase":"PHASE3","title":"Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer","status":"UNKNOWN","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2009-05-12","conditions":"Colorectal Cancer","enrollment":2000},{"nctId":"NCT04259944","phase":"PHASE2","title":"Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial","status":"UNKNOWN","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2020-06-16","conditions":"Colon Cancer","enrollment":140},{"nctId":"NCT05841134","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2023-06-01","conditions":"MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin","enrollment":25},{"nctId":"NCT02974556","phase":"PHASE3","title":"Proactive Management of Endoperitoneal Spread in Colonic Cancer","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2024-03-01","conditions":"Colon Cancer, Intraperitoneal Rectal Cancer","enrollment":140},{"nctId":"NCT03748680","phase":"PHASE2","title":"IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer","status":"UNKNOWN","sponsor":"Karen-Lise Garm Spindler","startDate":"2018-10-01","conditions":"Colorectal Cancer, Circulating Tumor DNA, Adjuvant Chemotherapy","enrollment":64},{"nctId":"NCT02231086","phase":"PHASE3","title":"Adjuvant HIPEC in High Risk Colon Cancer","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2015-03","conditions":"Colorectal Neoplasms, Peritoneal Neoplasms","enrollment":204},{"nctId":"NCT01092481","phase":"PHASE3","title":"Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2010-01-26","conditions":"Colon Cancer","enrollment":1580},{"nctId":"NCT03422601","phase":"","title":"Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment","status":"UNKNOWN","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2017-07-13","conditions":"Colorectal Cancer, Stage III Colon Cancer","enrollment":1122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CAPOX 6 month","genericName":"CAPOX 6 month","companyName":"NRG Oncology","companyId":"nrg-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a thymidylate synthase inhibitor. Used for Colorectal cancer, Breast cancer, Stomach cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}